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S u m m a r y
The field of urology continues to evolve. There have been several major breakthroughs 
in the diagnosis and management of many urological diseases over last few decades. 
Just to mention the development of endourology, a subspecialty which not only does en-
compass visualisation of the upper and lower urinary tract but also modern management 
of diseases of the prostate. Other examples include ever growing field of laparoscopy or 
robotic urology itself to mention but the few.
Moreover, there has been a significant progress with regards to improvement of exist-
ing and development of new imaging modalities including magnetic resonance imaging 
which has advanced from being a standard anatomical imaging modality to one provid-
ing vital functional information about the cellularity of solid tissues (diffusion weighted 
imaging), perfusion parameters in neoplasms (dynamic contrast imaging), and relative 
concentration of intracellular metabolites (spectroscopy). Furthermore, recent advances 
in cancer genetics and genomics have changed our management paradigms in major 
urologic malignancies and have led to the development of new markers for detection, 
prognostication, and tailoring the most effective therapy in patients with cancers of the 
urinary tract.
This review discusses the recent advances in diagnosis and management of pros-
tate, bladder, and renal cancers, as well as benign prostatic hyperplasia and urolithi-
asis.
S t r e s z c z e n i e
Urologia jest dynamicznie rozwijającą się dziedziną medycyny. W ostatnich dekadach 
dokonano przełomowych odkryć zarówno w zakresie diagnostyki, jak i leczenia chorób 
układu moczowo-płciowego. Jednym z nich jest rozwój endourologii, nowo wyłonionej 
poddyscypliny, która nie tylko pozwala na inspekcję od wewnątrz górnego i dolnego od-
cinka układu moczowego, ale również jest dedykowana do leczenia nowymi sposobami 
chorób stercza i pęcherza moczowego. Kolejnym przykładem jest powszechna dostęp-
ność chirurgii laparoskopowej, zarówno manualnej, jak i z asystą robota. Ponadto nadal 
rozwijane są dotychczasowe oraz tworzone nowe metody obrazowania chorób układu 
moczowego, jak na przykład rezonans magnetyczny, który ewoluował od bycia standar-
dowym badaniem anatomicznym do badania, które dostarcza informacji czynnościowych 
dotyczących komórek tkanek litych (obrazy ważone dyfuzyjnie), informacji na temat prze-
pływu krwi w tkankach (obrazowanie dynamiczne z wykorzystaniem środka kontrastowe-
go) oraz pozwala na ocenę stężenia wybranych związków w badanym narządzie (spek-
troskopia rezonansu magnetycznego). Z kolei najnowsze osiągnięcia w zakresie genetyki 
i genomiki nowotworów w sposób istotny doprowadziły do zmian w postępowaniu w przy-
padkach nowotworów układu moczowego. Składa się na to m.in. odkrycie nowych marke-
rów nowotworowych ułatwiających wykrywalność, prognozowanie oraz dobór właściwego 
leczenia chorych.
W opracowaniu przedstwiono bieżące osiągnięcia w zakresie diagnostyki oraz lecze-
nia nowotworów gruczołu krokowego, pęcherza i nerek, łagodnego rozrostu stercza oraz 
kamicy dróg moczowych.
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INTRODUCTION
The specialty of urology is under incessant change. 
Much of which has resulted from improved technology 
and advanced equipment. Newer techniques for better 
diagnosis and treatment of common urological diseas-
es have enhanced early detection rates of urological 
cancers, reduced the operative trauma and optimized 
functional outcomes. Continuous improvements in 
management of malignancies, erectile dysfunction, 
benign prostatic hyperplasia (BPH), and renal stones 
have led to better quality of patients’ life.
Several various alternatives have been recently in-
vestigated either to improve the diagnosis or to en-
hance the sensitivity of common diagnostic tools and 
techniques used in detection or treatment of the most 
popular urological diseases such as cancers, BPH and 
renal stones. In this review, we have looked at the latest 
developments within the diagnosis and management 
of several most common urological conditions.
DETECTION AND MONITORING OF UROLOGICAL 
CANCERS
Renal cell carcinoma
Renal cell carcinoma (RCC) is one of the most com-
mon cancers dealt with by urologists. This malignancy 
is characterized by a lack of early warning signs, di-
verse clinical manifestations, and resistance to radia-
tion and chemotherapy (1). As with many other forms 
of cancer, patient outcome depends on the cancer 
stage and grade at diagnosis, its histological subtype, 
comorbidities and patient age. The 5-year overall sur-
vival for all types of RCC is 49%, whereas the 5-year 
survival rate after radical nephrectomy for stage I renal 
cell carcinoma, is approximately 94%, and for patients 
with stage IV disease is not higher than 20% (2, 3).
It is therefore of utmost importance to further im-
prove renal cell cancer detection rates at an earlier 
stage of the disease.
In recent years there has been an increased interest 
in the prognostic role of the tumor markers, which most 
likely will better predict the clinical disease prognosis 
in future. The roles of neutrophil gelatinase-associated 
lipocalin, C-reactive proteins, plasmatic kisspeptin, be-
ta-2-glickoprotein-1, alph-1-antitripsin and butyrylcho-
linesterase have been expanding (4-6). Additionally, 
latest data has suggested that nutritional screening 
is strongly associated with overall survival in patients 
treated with targeted agents for advanced renal cell 
carcinoma (7). Few recent studies have also shown 
that the metabolic profiles of glycolysis and pentose 
phosphate pathway in renal cell carcinoma, as well 
as, the pretreatment measurements of systemic in-
flammatory response, remain very important in overall 
patient’s prognosis (8). More and more is known with 
regard to some genetic disorders, as well as other pre-
disposing factors to renal cancer. The recent data has 
emphasized the role of piwi-interacting RNAs, FABP7 
protein, MIR-141 expression, and, in particular, the spe-
cific miRNA role in clear cell renal carcinoma treatment. 
These all are being used in critical suppression of renal 
cell carcinoma proliferation and metastasis (9-11).
Our knowledge of predicting RCC outcomes is still 
under development, especially in terms of tumor size, 
grading, staging, lymph node involvement, and BMI in 
both cancer-specific and overall survival but it will in-
evitably grew with further advancements in analysis of 
cancer specific biomolecules and markers.
The role of imaging in the management of renal tu-
mors has progressed in the past few years. The latest 
studies have shown that perinephric fat surface den-
sity (PnFSD) can significantly predict surgical com-
plexity and perioperative outcomes of kidney surgery, 
especially robot-assisted partial nephrectomy (12). 
Moreover, new anatomical scoring systems for assess-
ing technical complexity of kidney surgery have been 
introduced. Multiphasic computed tomography (CT), 
as well as the CT guided renal biopsies have become 
more useful than ever before in terms of diagnosis and 
management of small renal masses (13, 14). Targeted 
dual-modality imaging of renal cell carcinoma is still 
under investigation but preliminary results seem quite 
promising.
Prostate cancer
R O L E  O F  M R I  I N  P R O S T A T E  C A N C E R 
D E T E C T I O N
Prostate cancer (PCa) is the most common non-
cutaneous cancer among males (15, 16). Although 
prostate cancer can be slow growing, the disease ac-
counts for approximately 10% of cancer-related deaths 
in men (17). The diagnostic gold standard in prostate 
cancer (PCa) detection is based on abnormal digital 
rectal examination, an elevated serum PSA, and confir-
matory transrectal ultrasound guided biopsy.
In recent years, multiparametric MRI (mpMRI) has 
emerged as an appealing tool facilitating significant 
prostate cancers pick-up rate (18). New data has sug-
gested superiority of MRI-guided biopsy over non-tar-
geted TRUS biopsy in detection of clinically significant 
disease (19). The addition of mpMRI to biopsy seems 
to have made an important step forward towards devel-
oping an ideal diagnostic test, with greater detection of 
more clinically significant lesions.
TREATMENT OF UROLOGICAL CANCERS
Expanding role of robotic surgery
Robot-assisted surgery is a technical solution us-
ing robotic systems in surgical procedures. It was 
developed to overcome limitations of minimally in-
vasive procedures and to expand the capabilities of 
surgeons (20). This technique allows surgeons to en-
hance precision, flexibility and control, which are not 
otherwise possible with conventional techniques. It is 
safe, reproducible and offers several advantages to 
patients. With this method minimally invasive surgery 
is limitless. The benefits include: faster patient recov-
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ery, shorter hospital stay, less pain and blood loss, 
smaller risk of complications including infections, less 
noticeable scars. With robotic procedure surgeons can 
perform complex operations that would have been oth-
erwise difficult or impossible with conventional tech-
niques. One of the major advances offered by robot-
assisted surgery are remote control and unmanned 
procedures.
Robotic surgery is in many ways similar to laparo-
scopic surgery. It can be performed through smaller 
incisions compared to an open surgery. The most 
widely used clinical robotically-assisted surgical sys-
tem includes a camera arm and mechanical arms with 
surgical instruments which are attached to them. Sur-
geon seats at a computer console, which gives him 
a high-definition, magnified 3D view of the surgical site. 
In this technique instead of directly moving the instru-
ments, the surgeon uses one of two methods to control 
the whole system. It can be a direct telemanipulator 
or a computer control. Former is a remote manipula-
tor that allows the surgeon to perform standard move-
ments during surgery, while the robotic arms carry 
out those movements using end-effectors (e.g. cut-
ting tools, graspers), and manipulators to perform the 
current surgery on the patient. In computer-controlled 
systems the surgeon uses a computer to control the 
robotic arms and its end-effectors but telemanipulators 
can also be used. Advantage of using this computer-
ized method is that the surgeon does not have to be 
present. Performer can be anywhere in the world and 
this method leads to the possibility of remote surgery.
Compared with other minimally invasive surgery ap-
proaches and techniques, robotic surgery gives the 
surgeon a better control over the surgical movements 
and a better view of the surgical site. Moreover, sur-
geons no longer have to stand throughout the surgery 
and do not tire as quickly. Naturally occurring hand 
tremors are always filtered out by the robot’s software. 
Finally, the surgical robot can be continuously used by 
rotating surgical teams.
In urology robot-assisted surgery has become very 
popular (21). As a consequence, a brand new inter-
disciplinary field called Urology Robotics or URobotics 
has emerged.
ROBOT-ASSISTED RENAL SURGERY
Kidney surgery is one of the most dynamically de-
veloping branches of robot-assisted surgery. This 
technique is used with high success rates in:
– robot-assisted pyeloplasty for ureteropelvic junction 
obstruction (both in pediatric and adult population),
– robotic radical nephrectomy (RRN),
– robotic partial nephrectomy (RPN, with ultra-
sound, TilePro multi-input display or fluorescence 
navigating),
– robotic radical nephroureterectomy,
– robotic ureter reimplantation (22-25).
Robot-assisted surgery of the upper urinary tract is 
becoming a routine method with excellent assistant. 
It is the translation of traditional surgery in a minimally 
invasive fashion offering more meticulous handling 
and miniaturisation of instruments. Reported data has 
proved feasibility of this technique, good oncological 
results and promising functional outcomes.
Robot-assisted laparoscopic prostatectomy
Robot-assisted laparoscopic prostatectomy (RALP) 
is a technique, which has gained widespread accep-
tance in the United States. Nowadays, about 84% of 
all radical prostatectomies in the U.S. are being done 
using robotic procedures. Similar trends have been 
observed in Europe, where RALP is becoming more 
available (26).
Robotic prostatectomy offers minimally invasive ap-
proach (27). This technique simplifies creation of a wa-
tertight vesicourethral anastomosis, which is a chal-
lenging step of radical prostatectomy (28). It allows 
surgeon to perform a proper dissection in the vesico-
prostatic septum, better identification of the urethral 
tube, as well as bladder neck preservation (29). All of 
which have resulted with improved urinary continence.
In addition, RALP may lead to better potency rates 
in comparison to RRP (30). However, the oncological 
outcomes remain similar to those of RALP, LRP and 
RRP (31).
Current best evidence favors robotic prostatec-
tomy over alternative approaches for selected out-
comes (32). However, the aforementioned observa-
tions are based on a low level of evidence reflecting 
considerable uncertainty about its true benefits and 
harms.
IMMUNOTHERAPY IN UROLOGIC ONCOLOGY
After decades of research cancer immunotherapy 
has become an important new field of interest and sub-
jects for clinical studies including urology. The results 
have raised hope that immunotherapy may provide 
new treatment options of prostate, bladder and renal 
cell carcinomas in future. Up until now we have had 
only general overview of this knowledge. Nowadays 
we are observing a significant growth in this field of 
urology. Future outlook of immunotherapy in the treat-
ment of urologic malignancies seems promising.
Prostate cancer had the first approved vaccine treat-
ment. One of the most notable therapeutic cancer vac-
cines is the Sipuleucel-T. Lots of clinical trails are un-
derway and preliminary results are encouraging.
Additionally, some new immune modulatory agents 
may assist treatment in the challenging PCa cases. 
They can be administered either alone or in combina-
tion to patients with prostate cancer. Ipilimumab has 
been at the vanguard of this new immunotherapy ap-
proach. It targets the CTLA-4 checkpoint molecule on 
the activated immune cells (33).
Renal cell carcinoma is regarded as an immunologic 
tumor and studies exploring new targets in immuno-
therapy are currently underway. Novel agents for RCC 
treatment focusing on dendritic cell, checkpoint inhibi-
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tion and peptide vaccination alone or in combination 
with established therapies will soon be introduced. The 
cytokines interleukin-2 (IL-2) and interferon-alpha cause 
a reduction in tumor mass in approximately 10-20% of 
patients and enable durable remissions in those sub-
sets of patients. Moreover, adoptive cell therapy can 
help in renal cancer treatment. In this method immune 
cells are removed from the patient, then modified with 
genetic procedures or combined with some chemicals 
to enhance their activity. Next they are reintroduced 
into patient aiming to either trigger or strengthen the 
immunological anti-cancer response (34, 35).
Immunotherapy in bladder cancer is an extensive 
area of urology. Use of BCG has reduced the risk of 
bladder cancer recurrence and increased percentage 
of cases with a complete response after surgery. On-
going immunotherapeutic clinical trials in patients with 
bladder cancer have been focusing on oncolytic virus 
therapy with tumor cells self-destruction, checkpoint 
inhibitors with anti-PD-L1(MPDL3280A) antibody and 
anti-PD-1 (Nivolumab) antibody to unleash or enhance 
pre-existing anti-cancer immune responses. There 
have also been several trials of vaccines especially with 
HS-410 and DEC-205-NY-ESO-1 fusion protein vaccine 
to induce immune response against tumor-specific or 
tumor-associated antigens. Recently some combined 
particles have been produced. There are combinations 
of cytokines and special antibodies, which recognize 
peptides on the surface of tumor cells (36-38).
NEW OPTIONS IN THE MANAGEMENT OF BENIGN 
PROSTATIC HYPERPLASIA
Transurethral resection of the prostate (TURP) has 
been the gold standard treatment in men with lower uri-
nary tract symptoms caused by benign prostatic enlarge-
ment, for more than 60 years. Its role, however, has been 
increasingly challenged by the development of minimally 
invasive techniques including laser procedures.
There are several types of lasers that are used in 
treatment of enlarged prostate, and include holium, 
thulium, or greenlight lasers (39-41). The most inves-
tigated laser procedure for BPH surgery is holium la-
ser. It provides reliable histology and has comparable 
results to those of TURP or open surgery. Green light 
laser is relatively popular, safe, effective, easy to learn 
and can be used in anticoagulated patients. The dis-
advantage of the technique is that it does not provide 
tissue for histological examination, however.
In the 21st century, laser devices have challenged 
TURP. Therefore, TURP needs to be further optimized by 
reducing its rate of complications in order to remain still the 
gold standard and the mainstay of BPH surgical treatment.
ADVANCEMENTS IN THE MANAGEMENT 
OF UROLITHIASIS
Thanks to significant progress within technology 
interventional stone treatment patterns have consider-
ably changed over the years. Nowadays, open stone 
surgery has been replaced by minimal-invasive tech-
niques. Although conventional semi-rigid uretero-
renoscopy (URS) and percutaneous nephrolithoto-
my (PCNL) seem to be the most common procedures, 
the frequencies of flexible ureterorenoscopy (FURS) 
and retrograde intrarenal surgery (RIRS) have been 
also increasing (42, 43).
The indications for FURS and RIRS have also ex-
panded, though PCNL still remains the gold-standard 
treatment for large and/or complex renal stones. Ac-
cording to the newest data, there have been a high 
success rates in treating larger stones (2-3 cm) using 
a flexible ureterorenoscopy (43). FURS also appears 
to be a very safe technique, and can serve as an al-
ternative to PCNL in selected patients with large renal 
calculi.
A new way of treatment, that also may be consid-
ered is a combination of procedures. Endoscopic 
Combined IntraRenal Surgery (ECIRS) is a fusion of 
PCNL and RIRS, that facilitates exploration of the entire 
renal cavity (44). Another combination of procedures is 
extracorporeal lithotripsy endoscopically controlled by 
ureterorenoscopy (45).
Innovative solution, which may revolutionise the 
future urology is robot-assisted flexible ureterorenos-
copy (46). Its aim is to improve the FURS outcomes re-
ducing side effects of both the surgeons and the endo-
scopes. It provides a suitable and safe platform, away 
from radiation source with significant improvement of 
ergonomics.
CONCLUSIONS
Urology is a rapidly changing and exciting 
area of medicine. Several new techniques and 
developments have been introduced in recent 
years aimed to improve the diagnosis and man-
agement of the most common urological con-
ditions. Technological advances not only have 
facilitated better and earlier detection of urologi-
cal diseases, but they also have provided more 
accurate, minimally invasive treatment tools with 
high efficacy, safety, and tolerability which have 
further allowed achieving better treatment out-
comes. Further novel techniques and equipment 
will inevitably emerge and will be hopefully em-
braced and employed by urologists in their day 
to day clinical practice.
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